Comment · Thu, February 13, 2014
MDA with a SSRI
Original post in this thread
wolpertinger777 · 12 points
I'm a huge fan of MDA for its psychedelic properties. It has a really special "outrospection" that I have yet to experience in other substances.
The only problem for me is its supposed neurotoxicity because of monoamine release. Would using an SSRI (such as kanna) remove the serotonin releasing properties of the drug and therefore curb the issue of neurotoxicity?
I know that the compound might feel a little different without the serotonin release and the psychedelia might require higher dosages but would it still be effective?
TO SUM UP: Would using an SSRI (such as kanna) with MDA block the serotonin releasing properties and thereby create a non-neurotoxic dopamine/norepinephrine releasing agent with 5ht2a agonism?
What they were answering
Herperderperton · 1 points
6-APB still has direct interaction with SERT, DAT and NET. I'd like to see if a pure 5-HT2b agonist causes serotonin release, or it requires additional interactions with the SERT, suggesting a combined mechanism. MDA is a slightly weaker entactogen than MDMA in most peoples eyes, rather than a much stronger one. I know that isn't pharmacological evidence, but it suggests that something aside from 5-HT2b agonism is associated with serotonin release if it is a stronger agonist at this receptor.
EDIT: Turns out they aren't significantly different in their efficacy as serotonin releasing agents, despite the huge difference in 5-HT2b receptor binding affinity http://bitnest.ca/Silo42/10.1016/0091-3057(91)90005-M.pdf
u/MisterYouAreSoDumb
I would agree. It has to be a combined mechanism. I'll have to do some more digging. I had a good study showing the higher 5-HT release from 6-APB, but I cannot seem to find it right now. I'll try to tomorrow after I get some sleep.